IL17A and rheumatoid arthritis: Importantly, recent clinical trials with short duration IL-17 antagonistic therapy in established rheumatoid arthritis (RA) have provided the direct evidence in pathological role of IL-17 in RA and indicated that blockade of IL-17 in humans may represent a valid therapeutic approach [16].